CYBIN INC (CYBN) Stock Price, Quote, News and Overview
NYSEARCA:CYBN - NYSE Arca - CA23256X4075 - Common Stock - Currency: USD
CYBN Quote, Performance and Key Statistics
6.72
-0.09 (-1.32%)
The current stock price of CYBN is 6.72 USD. In the past month the price increased by 13.71%. In the past year, price decreased by -49.47%.
CYBN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 69.15 | 852.20B | ||
| JNJ | JOHNSON & JOHNSON | 15.55 | 376.68B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.21 | 294.98B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.46 | 224.15B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 19.25 | 222.58B | ||
| MRK | MERCK & CO. INC. | 10.94 | 214.40B | ||
| PFE | PFIZER INC | 7.6 | 138.44B | ||
| SNY | SANOFI-ADR | 14.24 | 134.52B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.84 | 102.14B | ||
| GSK | GSK PLC-SPON ADR | 9.1 | 80.75B | ||
| ZTS | ZOETIS INC | 26.42 | 69.76B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.24 | 48.12B |
Related stock screener links
About CYBN
Company Profile
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. The company has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Company Info
CYBIN INC
100 King Street West, Suite 5600
TORONTO ONTARIO CA
CEO: Doug Drysdale
Employees: 50
Company Website: https://www.cybin.com
Investor Relations: http://ir.cybin.com/overview/default.aspx
Phone: 19087648385
CYBIN INC / CYBN FAQ
What is the stock price of CYBIN INC today?
The current stock price of CYBN is 6.72 USD. The price decreased by -1.32% in the last trading session.
What is the ticker symbol for CYBIN INC stock?
The exchange symbol of CYBIN INC is CYBN and it is listed on the NYSE Arca exchange.
On which exchange is CYBN stock listed?
CYBN stock is listed on the NYSE Arca exchange.
What is CYBIN INC worth?
CYBIN INC (CYBN) has a market capitalization of 135.07M USD. This makes CYBN a Micro Cap stock.
How many employees does CYBIN INC have?
CYBIN INC (CYBN) currently has 50 employees.
What are the support and resistance levels for CYBIN INC (CYBN) stock?
CYBIN INC (CYBN) has a support level at 6.71 and a resistance level at 7.21. Check the full technical report for a detailed analysis of CYBN support and resistance levels.
Should I buy CYBIN INC (CYBN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYBN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYBN, evaluating the profitability, health, valuation and growth aspects
- CYBIN INC (CYBN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYBIN INC (CYBN) Sales and EPS estimates to see what analysts future expectations are.
- CYBIN INC (CYBN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYBIN INC (CYBN) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYBIN INC (CYBN) Stock Chart to make your own analysis
- CYBIN INC (CYBN) Latest news and press-releases to stay up to date.
Does CYBIN INC (CYBN) stock pay dividends?
CYBN does not pay a dividend.
CYBN Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CYBN. When comparing the yearly performance of all stocks, CYBN is a bad performer in the overall market: 89.95% of all stocks are doing better.
CYBN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYBN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to CYBN. The Buy consensus is the average rating of analysts ratings from 7 analysts.